Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-17
    E.g., 2018-10-17

Articles

26860 items
11:56 AM, Aug 31, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Novartis' PI3Kα inhibitor meets in Phase III for breast cancer

Novartis AG (NYSE:NVS; SIX:NOVN) said alpelisib (BYL719) met the primary endpoint in the Phase III SOLAR-1 trial to treat advanced breast cancer in previously treated patients that harbor the phosphoinositide 3-kinase (PI3K) catalytic subunit α...
11:51 AM, Aug 31, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Esperion combo lowers LDL-C in Phase III for high-risk ASCVD

Esperion Therapeutics Inc. (NASDAQ:ESPR) said its bempedoic acid/ezetimibe combination pill met the primary endpoint of reducing LDL-C in the Phase III 1002-053 trial to treat hypercholesterolemia in high-risk atherosclerotic cardiovascular disease (ASCVD) patients on maximally...
11:51 AM, Aug 31, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

J&J's Xarelto misses in pair of Phase III trials in acute medically ill and heart failure patients

Johnson & Johnson (NYSE:JNJ) reported that anticoagulant Xarelto rivaroxaban missed the primary endpoints in both the Phase III MARINER and COMMANDER HF trials. Data were presented at the European Society of Cardiology meeting in Munich...
11:50 AM, Aug 31, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Taiwan Liposome OA therapy hits mark in Phase II trial

Months after proposing a second listing on NASDAQ, Taiwan Liposome Co. Ltd. (TPEx:4152) said the lower of two doses of its lead candidate TLC599 met the primary endpoint in a double-blind Phase II trial to...
11:47 AM, Aug 31, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Pfizer eyes submission after TTR readout

Pfizer Inc. (NYSE:PFE) reported detailed data from the Phase III ATTR-ACT trial of tafamidis meglumine in patients with transthyretin (TTR) cardiomyopathy showing that the drug led to a 30% improvement in all-cause mortality. Pfizer has identified...
11:29 AM, Aug 31, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Patient death in Sophiris' prostate cancer trial deemed unrelated to topsalysin

Sophiris Bio Inc. (NASDAQ:SPHS) said that the patient death reported in June from a Phase IIb trial evaluating topsalysin (PRX302) to treat localized prostate cancer is unlikely to be related to either topsalysin or the...
11:27 AM, Aug 31, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Prevencio's HART PAD test detects PAD in diabetes patients

Prevencio Inc. (Kirkland, Wash.) said its HART PAD test diagnosed peripheral artery disease (PAD) in a cohort of 94 diabetic patients with 95% accuracy. Data were presented at the European Society of Cardiology meeting in...
11:24 AM, Aug 31, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Kyowa's KW-6356 improves motor symptoms in Phase IIa for early PD

Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) said low- and high-dose oral KW-6356 both improved motor symptoms compared with placebo in a Phase IIa trial in 168 patients with early Parkinson's disease who had not received...
10:38 AM, Aug 31, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Biohaven's BHV-0223 meets in Phase II/III for speaking anxiety

Biohaven Pharmaceuticals Holding Co. Ltd. (NYSE:BHVN) said BHV-0223 met the primary endpoint of reducing anxiety while performing an anxiety-provoking speech task vs. placebo in a U.S. Phase II/III trial to treat social anxiety disorder. The...
10:38 AM, Aug 31, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

MC2's non-greasy psoriasis cream superior to Taclonex in Phase III

MC2 Therapeutics A/S (Horsholm, Denmark) said MC2-01, its non-greasy topical cream formulation of calcipotriene/betamethasone dipropionate, was superior to Taclonex, a marketed formulation of the combination, on the primary and secondary endpoints in a single-blind Phase...

Pages